Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma

Figures & data

Table 1 Ongoing clinical trials evaluating immune checkpoint inhibitors in HNSCC

Trial identifier	Drug	Phase	Immune checkpoint target	Disease/tumor type	Primary outcome measures
NCT01848834	Pembrolizumab (MK-3475)	IB	PD-1	R/M HNSCC	OR ORR OS PFS
NCT02105636	Nivolumab	III	PD-1	R/M HNSCC	ORR OS
NCT02358031	Pembrolizumab (MK-3475)	III	PD-1	R/M HNSCC	PFS
NCT02296684	Pembrolizumab (MK-3475)	II	PD-1	Locoregionally advanced surgically resectable HNSCC	Locoregional recurrence rates; distant failure rate
NCT02252042	Pembrolizumab	III	PD-1	R/M HNSCC	PFS, OS
NCT02255097	Pembrolizumab	II	PD-1	R/M HNSCC	ORR
NCT02289209	Pembrolizumab + RT	II	PD-1	Locoregional inoperable recurrence or 2nd primary HNSCC	PFS
NCT0233558	Nivolumab	II	PD-1	R/M nasopharyngeal cancer	Objective tumor response per RECIST criteria
NCT01693562	Durvalumab (MEDI-4736)	I/II	PD-L1	Solid tumors (including HNSCC) refractory to standard therapy	OR
NCT02499328	Durvalumab (MEDI-4736) + either AZD9150 or AZD5069	I/II	PD-L1	R/M HNSCC	Safety/efficacy ORR
NCT02291055	Durvalumab (MEDI-4736) + ADXS11-001	I/II	PD-L1	Previously treated locally advanced or metastatic cervical or HPV^+ HNSCC	Safety/efficacy
NCT01860430	Ipilimumab-concurrent cetuximab and IMRT	IB	CTLA-4	AJCC stage III/IVB HNSCC, excluding T1N1	Ipilimumab dose
NCT01935921	Ipilimumab-concurrent cetuximab and IMRT	I	CTLA-4	R/M HNSCC	PFS Ipilimumab dose
Combinatorial immunotherapy
NCT02551159	Durvalumab (MEDI-4736) + tremelimumab	III	PD-L1 and CTLA-4	R/M HNSCC	PFS, OS
NCT02369874	Durvalumab (MEDI-4736) + tremelimumab	III	PD-L1 and CTLA-4	R/M HNSCC	OS, PFS
NCT02319044	Durvalumab (MEDI-4736) +/− tremelimumab	II	PD-L1 and CTLA-4	R/M HNSCC	ORR
NCT02262741	Durvalumab (MEDI-4736) + tremelimumab	I	PD-L1 and CTLA-4	R/M HNSCC	Safety

Abbreviations: PFS, progression-free survival; ORR, overall response rate; OS, overall survival; RT, radiation therapy; IMRT, intensity-modulated radiotherapy; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed cell death 1; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; R/M, recurrent or metastatic; HPV, human papilloma virus; AJCC, American Joint Committee on Cancer; OR, odds ratio; RECIST, response evaluation criteria in solid tumors.